Neurizon Creates Liquid Formula to Improve Accessibility of ALS Treatment

Neurizon creates liquid formula to improve accessibility of ALS treatment

NUZ develops oral liquid formula of NUZ-001 ALS treatment Company expects to both improve patient experience and drugs commercial potential New formula to be included in upcoming human clinical trials   Special Report: Neurizon Therapeutics has developed a new oral liquid formulation of its NUZ-001 drug for the treatment of Amyotrophic Lateral Sclerosis (ALS) in a move expected to improve accessibility and ease administration of the treatment. T…

LifeArc joins new global initiative to accelerate drug discovery for ALS/MND treatments

LifeArc joins new global initiative to accelerate drug discovery for ALS/MND treatments  LifeArc has become a partner of the Longitude Prize on ALS: a £7.5 million global programme that incentivises the use of artificial intelligence (AI) to transform drug discovery for the treatment of amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), which launches today (25 June 2025).  Although some very limited treatments exist …